Polycystic Ovary Syndrome and Endometrial Cancer

Ramesan Navaratnarajah; Ouma C. Pillay; Paul Hardiman

doi:10.1055/s-2007-992926

Seminars in Reproductive Medicine, Table of Contents

Semin Reprod Med 2008; 26(1): 062-071
DOI: 10.1055/s-2007-992926

Polycystic Ovary Syndrome and Endometrial Cancer

Ramesan Navaratnarajah¹ , Ouma C. Pillay¹ , Paul Hardiman¹

¹University Department of Obstetrics and Gynaecology, Royal Free and University College Medical School, University College London, London, United Kingdom

Abstract

ABSTRACT

An association between polycystic ovary syndrome (PCOS) and endometrial carcinoma was first suggested in 1949. Since then, several studies have been published that appear to support this association, and it is common practice among gynecologists and physicians to prescribe hormonal treatment to reduce this perceived risk, although there is no consensus as to the subgroup of PCOS in whom this is required. The mechanism(s) underlying any association are also unclear, but it is again widely assumed that chronic anovulation, which results in continuous estrogen stimulation of the endometrium unopposed by progesterone, is a major factor. However, obesity, hyperinsulinemia, and hyperandrogenism, which are also features of PCOS, are risk factors for endometrial carcinoma, but it does not necessarily follow that the incidence or mortality from endometrial cancer is increased in women with the syndrome. Potential strategies to prevent endometrial cancer in PCOS women are discussed.

KEYWORDS

Polycystic ovary syndrome - polycystic ovaries - endometrial hyperplasia - endometrial carcinoma

Full Text

References

REFERENCES

1 Speert H. Carcinoma of the endometrium in young women. Surg Gynecol Obstet. 1949; 88 332-336
2 Hardiman P, Pillay O S, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet. 2003; 361 1810-1812
3 Velazquez E M, Mendoza S G, Hamer T, Sosa F, Glueck C J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinaemia, insulin resistance, hyperandrogenaemia, and systolic blood pressure, whilst facilitating normal menses and pregnancy. Metabolism. 1994; 43 647-654
4 The Rotterdam ESHRE/ASRM Group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19 41-47
5 Jackson R L, Dockerty M B. The Stein-Leventhal syndrome: analysis of 43 cases with special reference to association with endometrial carcinoma. Am J Obstet Gynecol. 1957; 73 161-173
6 Stein I F, Leventhal M L. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935; 29 181-189
7 Jemal A, Thomas A, Murray T, Thun M. American Cancer Society Cancer Statistics, 2002. CA Cancer J Clin. 2002; 52 23-47
8 Coleman M P, Rachet B, Woods L M et al.. Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001. Br J Cancer. 2004; 90 1367-1373
9 Bray F, dos Santos Silva I, Moller H, Weiderpass E. Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. Cancer Epidemiol Biomarkers Prev. 2005; 14 1132-1142
10 Ramzy I, Nisker J A. Histologic study of ovaries of young women with endometrial carcinoma. Am J Clin Pathol. 1979; 71 253-256
11 Soliman P T, Oh J C, Schmeler K M. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol. 2005; 105 575-580
12 Dockerty M B, Lovelady B, Foust G T et al.. Carcinoma of corpus uteri in young women. Am J Obstet Gynecol. 1951; 61 966-981
13 Coulam C B, Annegers J F, Kranz J S. Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol. 1983; 61 403-407
14 Escobedo L G, Lee N C, Peterson H B, Wingo P A. Infertility-associated endometrial cancer risk may be limited to specific subgroups in infertile women. Obstet Gynecol. 1991; 77 124-128
15 Gallup D G, Stock R J. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol. 1984; 64 417-420
16 Dahlgren E, Friberg L G, Johansson S. Endometrial carcinoma: ovarian dysfunction-a risk factor in young women. Eur J Obstet Gynecol Reprod Biol. 1991; 41 143-150
17 Konishi I, Koshiyama M, Mandai M et al.. Increased expression of LH/hCG receptors in endometrial hyperplasia and carcinoma in anovulatory women. Gynecol Oncol. 1997; 65(2) 273-280
18 Ho S P, Tan K T, Pang M W, Ho T H. Endometrial hyperplasia and the risk of endometrial carcinoma. Singapore Med J. 1997; 38 11-15
19 Pierpoint T, McKeigue P, Isaacs A J et al.. Mortality of women with polycystic ovary syndrome at long term follow up. J Clin Epidemiol. 1998; 51 581-586
20 Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil. 2000; 3 101-105
21 Pillay O C, Wong Te Fong L F, Crow J C et al.. The association between polycystic ovaries and endometrial cancer. Hum Reprod. 2006; 21(4) 924-929
22 Luque-Ramirez M, Alvarez-Blasco F, Mendieta-Azcona C, Botella-Carretero J I, Escobar-Morreale H F. Obesity is the major determinant of the abnormalities in blood pressure found in young women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 2007; 92 2141-2148
23 Cibula D, Cifkova R, Fanta M, Poledne R, Zivny J, Skikoba J. Increased of NIDDM, arterial hypertension and coronary artery disease in perimenopausal women with a history of PCOS. Hum Reprod. 2000; 15 785-789
24 Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril. 2002; 77 1095-1105
25 Friberg E, Orsini N, Mantzoros C S, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia. 2007; 50 1365-1374
26 Friberg E, Mantzoros C S, Wolk A. Physical activity and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2006; 15 2136-2140
27 Glintborg D, Henriksen J E, Andersen M et al.. Prevalence of endocrine diseases and abnormal glucose tolerance tests in 340 Caucasian premenopausal women with hirsutism as the referral diagnosis. Fertil Steril. 2004; 82 1570-1579
28 Chang S C, Lacey J V, Brinton L A et al.. Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP diet and health study. Cancer Epidemiol Biomarkers Prev. 2007; 16 723-730
29 Furberg A S, Thune I. Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort. Int J Cancer. 2003; 104 669-676
30 Birdsall M A, Farquhar C M. Polycystic ovaries in pre and post-menopausal women. Clin Endocrinol (Oxf). 1996; 44 269-276
31 Winters S J, Talbott E, Guzick D S, Zborowski J, McHugh K P. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertil Steril. 2000; 73 724-729
32 Lukanova A, Lundin E, Micheli A et al.. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer. 2004; 108 425-432
33 Nagamani M, Hannigan E V, Dillard E A, Van Dinh T. Ovarian steroid secretion in postmenopausal women with and without endometrial cancer. J Clin Endocrinol Metab. 1986; 62 508-512
34 Potischman N, Hoover R N, Brinton L A et al.. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst. 1996; 88 1127-1135
35 Schemeler K, Soliman P T, Sun C C, Slomovitz B M, Gershenson D M, Lu K H. Endometrial cancer in young, normal-weight women. Gynecol Oncol. 2005; 99 388-392
36 Jafari K, Javaheri G, Ruiz G. Endometrial adenocarcinoma and the Stein-Leventhal syndrome. Obstet Gynecol. 1978; 51 97-100
37 Farhi D C, Nosanchuk J, Silverberg S G. Endometrial adenocarcinoma in women under 25 years of age. Obstet Gynecol. 1986; 68 741-745
38 Nakanishi T, Ishikawa H, Suzuki Y, Inoue T, Nakamura S, Kuzuya K. Association between menopausal state and endometrial cancer. Int J Gynecol Cancer. 2001; 11 483-487
39 Pillay O C, Te Fong L F, Crow J C et al.. The association between polycystic ovaries and endometrial cancer. Hum Reprod. 2006; 21 924-929
40 Soslow R A, Shen P, Chung M H, Isacson C, Baergen R N. Cyclin D1 expression in high-grade endometrial carcinomas-association with histologic subtype. Int J Gynecol Pathol. 2000; 19 329-334
41 Giangrande P H, McDonnell D P. The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene. Rec Prog Horm Res. 1999; 54 291-313
42 Masafumi Koshiyama K I, Mandai M. Increased expression of LH/hCG receptors in endometrial hyperplasia and carcinoma in anovulatory women. Gynecol Oncol. 1997; 65 273-280
43 Dabizzi S, Noci I, Borri P et al.. Luteinizing hormone increases human endometrial cancer cells invasiveness through activation of protein kinase A. Cancer Res. 2003; 63 4281-4286
44 Baillargeon J-P, Carpentier A. Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity. Fertil Steril. 2007; 88 886-893
45 Pasquali R, Gamberi A. Polycystic ovary syndrome: a multifaceted disease from adolescence to adult age. Ann N Y Acad Sci. 2006; 1092 158-174
46 Nagamani M, Stuart C A. Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture. Am J Obstet Gynecol. 1998; 179 6-12
47 Bershtein L M, Gamaiunova V B, Kvachevskaia I O. The nature of hyperinsulinaemia (insulin resistance) in endometrial carcinoma: of plasma levels of insulin and c-peptide. Vopr Onkol. 2000; 46 191-195
48 Soliman P T, Wu D, Tortolero-Luna G et al.. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer. 2006; 106 2376-2381
49 Bik W, Baranowska-Bik A, Wolinska-Witort E. The relationship between metabolic status and levels of adiponectin and ghrelin in lean women with polycystic ovary syndrome. Gynecol Endocrinol. 2007; 23 325-331
50 Tada A, Sasaki H, Nakamura J, Yoshihama M, Terashima Y. Aromatase activity and the effect of estradiol and testosterone on DNA synthesis in endometrial carcinoma cell lines. J Steroid Biochem Mol Biol. 1993; 44 661-666
51 Apparao K B, Lovely L P, Gui Y. Elevated endometrial androgen receptor expression in women with polycystic ovarian syndrome. Biol Reprod. 2002; 66 297-304
52 Pillay O C, Leonard A, Sharkey A, Catalano R, Hardiman P. Endometrial gene expression in women with PCOS. Human Reprod. 2005; 20(Supp 1) 20
53 Chen Y, Wang Y, Li M. Expression of apoptosis regulatory protein bcl-2 and bax in endometrium of polycystic ovary syndrome. Zhonghua Fu Chan Ke Za Zhi. 1999; 34 652-654
54 MacLaughlan S D, Palomino W A, Mo B et al.. Endometrial expression of Cyr61: a marker of estrogenic activity in normal and abnormal endometrium. Obstet Gynecol. 2007; 110 146-154
55 Orio Jr F, Palomba S, Cascella T et al.. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab. 2005; 90 6072-6076
56 Palomba S, Russo T, Orio Jr F et al.. Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome. Hum Reprod. 2006; 21 457-465
57 Costello M F, Shrestha B, Eden J, Johnson N P, Sjoblom P. Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. Hum Reprod. 2007; 22 1200-1209
58 Cameron S T, Critchley H OD, Thong K J et al.. Effects of daily low dose mifepristone on endometrial maturation and proliferation. Hum Reprod. 1996; 11 2518-2526
59 Narvekar N, Cameron S, Critchley H OD, Lin S, Cheng L, Baird D T. Low-dose mifepristone inhibits endometrial proliferation and up-regulates androgen receptor. J Clin Endocrinol Metab. 2004; 89 2491-2497
60 Di Spiezio Sardo A, Radhakrishnan S. Endometrial carcinoma on continuous combined HRT: case report and literature review. Maturitas. 2004; 48 171-175

Mr. Paul Hardiman

Academic Department of Obstetrics and Gynaecology, Royal Free and University College Medical School, The Royal Free Hospital

Pond Street, London NW3 2PF, United Kingdom

Email: p.hardiman@medsch.ucl.ac.uk